Cette page a été traduite automatiquement et l'exactitude de la traduction n'est pas garantie. Veuillez vous référer au version anglaise pour un texte source.

Un essai de phase II sur la stimulation électrique de surface pour l'incontinence urinaire chez les hommes traités pour un cancer de la prostate

7 novembre 2026 mis à jour par: National Cancer Institute (NCI)

Background:

Men who are treated for prostate cancer often develop urinary leakage (incontinence). An experimental device that uses electrical impulses to stimulate pelvic floor muscles and surrounding tissues may help.

Objective:

To see if the Elidah device can reduce urinary incontinence after prostate treatment.

Eligibility:

Men aged 18 years and older who have had moderate urinary incontinence for at least 6 months after treatment for prostate cancer.

Design:

Participants will be in the study for about 9 weeks. They will be screened. They will have a physical exam with urine tests.

The Elidah device consists of a Controller and a GelPad. The Controller sets the strength of electrical impulses. The GelPad is placed against the skin under the pelvis.

Participants will be given an Elidah device and taught how to use it at home.

They will use the device once a day for 20 minutes at a time; they will do this 5 days a week for 6 weeks.

Participants will complete a daily log. They will record the strength of electrical impulses (0-35); the number of incontinence episodes; the type of incontinence episode; and the number of used pads.

Participants will do a pad weight test. For 3 days before and 3 days after using the Elidah device, they will collect all of their used pads for each 24-hour period into a sealed plastic bag. They will also collect a second set of bags that contain dry versions of each product used.

Participants will have clinic visits after using the device for 3 weeks and after finishing the 6 weeks of treatment.

Participants will complete 15-minute questionnaires.

Aperçu de l'étude

Description détaillée

Background:

  • Urinary incontinence is a common side effect of prostate cancer therapy that can negatively impact the quality of life.
  • Standard treatment includes an initial course of pelvic floor muscle exercises followed by surgical therapy if urinary incontinence persists.
  • Although pelvic floor muscle exercises can be successful in reducing urinary incontinence, compliance with exercises is poor.
  • The Elitone (registered trademark) device was recently cleared by the Food and Drug Administration (FDA) for use in women with stress urinary incontinence. This device provides a surface electrical muscle stimulation device designed to contract the pelvic floor muscles and has been shown to reduce incontinence in women using the product.
  • Recently, the electrode component (GelPad) of the device has been adapted for use in men by the manufacturing company, Elidah. The male version of the device is named the Elidah device.

Objective:

-To describe the efficacy of the Elidah device on male urinary incontinence

Eligibility:

  • Participants must be male.

  • Participants must have a history of urinary incontinence for at least 6 months after prostate cancer treatment.

  • Participants must have at least one of the following types of urinary incontinence:

    • stress urinary incontinence, defined as involuntary loss of urine on effort or physical exertion (e.g., sporting activities), or on sneezing or coughing;
    • urge urinary incontinence, defined as a compelling need to urinate, due to pain or an unpleasant sensation, that is difficult to defer.

Design:

  • This is a phase II trial testing the efficacy of the Elidah device in people treated for prostate cancer with stress and/or urge urinary incontinence.
  • Prior to treatment, participants will undergo baseline assessments including 24-hour pad weight testing and questionnaires relating to incontinence and quality of life.
  • Participants will self-administer the Elidah device treatment for 20 minutes per day, 5 days per week during a 6-week period in the at-home environment. Participants will maintain a Daily Log to record usage of the Elidah device, urinary leaks, and use of pads during each week of treatment.
  • Following 6 weeks of therapy, participants will undergo re-evaluation of symptoms and urinary incontinence via questionnaires and testing with the 24-hour pad weight test.

Type d'étude

Interventionnel

Inscription (Estimé)

41

Phase

  • Phase 2

Contacts et emplacements

Cette section fournit les coordonnées de ceux qui mènent l'étude et des informations sur le lieu où cette étude est menée.

Coordonnées de l'étude

Sauvegarde des contacts de l'étude

  • Nom: Debbie-Ann N Nathan, R.N.
  • Numéro de téléphone: (240) 858-3103
  • E-mail: dnathan@mail.nih.gov

Lieux d'étude

    • Maryland
      • Bethesda, Maryland, États-Unis, 20892
        • Recrutement
        • National Institutes of Health Clinical Center
        • Contact:
          • National Cancer Institute Referral Office
          • Numéro de téléphone: 888-624-1937

Critères de participation

Les chercheurs recherchent des personnes qui correspondent à une certaine description, appelée critères d'éligibilité. Certains exemples de ces critères sont l'état de santé général d'une personne ou des traitements antérieurs.

Critère d'éligibilité

Âges éligibles pour étudier

18 ans à 120 ans (Adulte, Adulte plus âgé)

Accepte les volontaires sains

Non

Sexes éligibles pour l'étude

Homme

La description

  • INCLUSION CRITERIA:

  • Participants must be male.

  • Participants must have a history of urinary incontinence for at least 6 months after local prostate cancer treatment.

  • Participants must have at least one of the following types of urinary incontinence:

    • stress urinary incontinence, defined as involuntary loss of urine on effort or physical exertion (e.g., sporting activities) or on sneezing or coughing
    • urge urinary incontinence, defined as a compelling need to urinate, due to pain or an unpleasant sensation, that is difficult to defer.
  • Participants must have moderate urinary incontinence defined as use of 1-4 pads per day by self-report at screening.

  • Participants must be able to read and write in English.

  • Age >= 18 years.

  • Eastern Cooperative Oncology Group (ECOG) performance status <= 2.

  • Ability to understand and the willingness to sign a written informed consent document.

EXCLUSION CRITERIA:

  • Change of therapy for prostate cancer planned during the study intervention.
  • History or symptoms of urinary retention (not an exclusion if this occurred before prostatectomy), extra-urethral incontinence, overflow incontinence.
  • Active urinary tract infection (UTI) at screening or history of recurrent urinary tract infections (>= 4 UTIs within the 12 months prior to the study treatment initiation).
  • History of complete denervation of the pelvic floor.
  • Severe obesity (body mass index [BMI] >35).
  • Pelvic pain/painful bladder syndrome.
  • Metal implant in the abdominal or pelvic area.
  • History of chronic cough with ongoing symptoms
  • An implanted cardiac device, history of untreated cardiac arrhythmia, or history of other heart problems.
  • History of epilepsy.
  • History of underlying neurologic/neuromuscular disorder that could contribute to urinary incontinence.
  • Change in medications prescribed for urinary incontinence within 2 weeks prior to the study treatment initiation.
  • Uncontrolled intercurrent illness evaluated by medical history and physical examination or social situations that would limit compliance with study requirements.

Plan d'étude

Cette section fournit des détails sur le plan d'étude, y compris la façon dont l'étude est conçue et ce que l'étude mesure.

Comment l'étude est-elle conçue ?

Détails de conception

  • Objectif principal: Traitement
  • Répartition: N / A
  • Modèle interventionnel: Affectation à un seul groupe
  • Masquage: Aucun (étiquette ouverte)

Armes et Interventions

Groupe de participants / Bras
Intervention / Traitement
Expérimental: 1/Elidah Device

Elidah device application.

The Elidah device is a modified version of the FDA approved ELITONE device cleared for use in the treatment of female stress urinary incontinence. For the current study, only minor modifications have been implemented with respect to the shape of the electrode component, providing a contour better suited to fit the male anatomy.

Que mesure l'étude ?

Principaux critères de jugement

Mesure des résultats
Description de la mesure
Délai
To describe the efficacy of the Elidah device treatment on male urinary incontinence
Délai: Baseline and within 2 weeks after completing treatment

Percent decrease in 24-hour pad weight after treatment with the Elidah device.

Baseline and within 2 weeks after completing treatment

Mesures de résultats secondaires

Mesure des résultats
Description de la mesure
Délai
To assess the safety of the Elidah device in men with urinary incontinence
Délai: 3 week visit and end of treatment visit

Frequency of adverse events among treated participants and reporting the results, by maximum grade of event and type of toxicity noted.

3 week visit and end of treatment visit
To assess alternative measures of efficacy of Elidah device on male urinary incontinence and bother
Délai: Baseline and at end of treatment visit

Evaluated by the number of pads and number of leaks before and after treatment. The mean of the percent reduction in the number of pads used per day following treatment will be computed along with 95% confidence intervals.

Baseline and at end of treatment visit
To assess participant-reported outcomes of Elidah device use for male urinary incontinence
Délai: Baseline and at end of treatment visit

The proportion of participants for which the I-QoL score improves by 2.5 points or more following six weeks of Elidah device use will be estimated. 95% confidence intervals for this proportion will be constructed.

Baseline and at end of treatment visit
To assess treatment compliance with the Elidah device
Délai: 3 week visit and end of treatment visit

A test of binomial proportions will be performed to assess whether the treatment noncompliance rate is above the unacceptability threshold.

3 week visit and end of treatment visit

Collaborateurs et enquêteurs

C'est ici que vous trouverez les personnes et les organisations impliquées dans cette étude.

Les enquêteurs

  • Chercheur principal: Deborah E Citrin, M.D., National Cancer Institute (NCI)

Publications et liens utiles

La personne responsable de la saisie des informations sur l'étude fournit volontairement ces publications. Il peut s'agir de tout ce qui concerne l'étude.

Dates d'enregistrement des études

Ces dates suivent la progression des dossiers d'étude et des soumissions de résultats sommaires à ClinicalTrials.gov. Les dossiers d'étude et les résultats rapportés sont examinés par la Bibliothèque nationale de médecine (NLM) pour s'assurer qu'ils répondent à des normes de contrôle de qualité spécifiques avant d'être publiés sur le site Web public.

Dates principales de l'étude

Début de l'étude (Réel)

15 février 2024

Achèvement primaire (Estimé)

1 décembre 2027

Achèvement de l'étude (Estimé)

1 mars 2028

Dates d'inscription aux études

Première soumission

1 décembre 2023

Première soumission répondant aux critères de contrôle qualité

1 décembre 2023

Première publication (Réel)

8 décembre 2023

Mises à jour des dossiers d'étude

Dernière mise à jour publiée (Réel)

10 novembre 2026

Dernière mise à jour soumise répondant aux critères de contrôle qualité

7 novembre 2026

Dernière vérification

6 novembre 2026

Plus d'information

Termes liés à cette étude

Plan pour les données individuelles des participants (IPD)

Prévoyez-vous de partager les données individuelles des participants (DPI) ?

OUI

Description du régime IPD

All IPD recorded in the medical record will be shared with intramural investigators upon request.

Délai de partage IPD

Clinical data available during the study and indefinitely.

Critères d'accès au partage IPD

Clinical data will be made available via subscription to BTRIS and with the permission of the study PI.

Type d'informations de prise en charge du partage d'IPD

  • PROTOCOLE D'ÉTUDE
  • SÈVE
  • CIF

Informations sur les médicaments et les dispositifs, documents d'étude

Étudie un produit pharmaceutique réglementé par la FDA américaine

Non

Étudie un produit d'appareil réglementé par la FDA américaine

Non

Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .

S'abonner